

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	F	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/834,760 04/12/2001		04/12/2001	Richard C. Austin	19874-000410	4286
20350	7590	01/17/2002			
		TOWNSEND AN	EXAMINER		
EIGHTH F		ROCENTER	ANGELL, JON E		
SAN FRAN	icisco, c	CA 94111-3834	ART UNIT	PAPER NUMBER	
				1633	C
				DATE MAILED: 01/17/2002	6

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No		Applicant(s)					
	•	09/834,760		AUSTIN ET AL.					
	Office Action Summary	Examiner		Art Unit					
		J. Eric Angell		1635					
	The MAILING DATE of this communication app		er sheet with the c	orrespondence ad	dress				
Period for Reply									
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status									
1)	Responsive to communication(s) filed on	•							
2a) □	·	— is action is non-	final.						
3)	Since this application is in condition for allowa	ance except for f	ormal matters, pr	osecution as to th	e merits is				
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.									
Disposition of Claims									
4)⊠ Claim(s) <u>1-46</u> is/are pending in the application.									
4a) Of the above claim(s) is/are withdrawn from consideration.									
5) Claim(s) is/are allowed.									
6)	Claim(s) is/are rejected.								
•	Claim(s) is/are objected to.								
8) Claim(s) <u>1-46</u> are subject to restriction and/or election requirement.									
Applicati	on Papers								
9) The specification is objected to by the Examiner.									
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.									
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).									
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.									
If approved, corrected drawings are required in reply to this Office action.									
12) The oath or declaration is objected to by the Examiner.									
Priority under 35 U.S.C. §§ 119 and 120									
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).									
a) All b) Some * c) None of:									
	1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No.								
	2. Certified copies of the priority documents have been received in Application No								
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>									
14)⊠ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).									
<ul> <li>a) ☐ The translation of the foreign language provisional application has been received.</li> <li>15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.</li> </ul>									
Attachmen	t(s)								
2) Notic	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s)	4) [ 5) [ 	Notice of Informal	y (PTO-413) Paper No Patent Application (PT					

Application/Control Number: 09/834,760

Art Unit: 1635

## **DETAILED ACTION**

## Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-15, drawn to a method of producing an exogenous protein in the cell,
     classified in class 435, subclass 69.1.
  - II. Claims 1-10 and 16-17, drawn to a method of inducing an endogenous protein in a cell, classified in class 435, subclass 68.1.
  - III. Claims 18-35, drawn to a method of treating/preventing a disease by inducing the expression of an exogenous protein, classified in class 514, subclass 44.
  - IV. Claims 18-30, 36, 37 and 46 drawn to a method of treating/preventing a disease by inducing the expression of an endogenous protein, classified in class 514, subclass 2.
  - V. Claims 38-45, drawn to a method of identifying a compound useful in treatment, classified in class 435, subclass 4.

The inventions are distinct, each from the other because of the following reasons:

1. Inventions I and III are unrelated to Inventions II and IV. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions I and III are not disclosed as capable of use with inventions II and IV and have different modes of function and different effects. The function

Application/Control Number: 09/834,760

Art Unit: 1635

المنجر رخي

and effects of Inventions I and III is to induce the expression of an exogenous gene while the functions and effects of Inventions II and IV are to induce the expression of an endogenous gene.

- 2. Inventions I and II are unrelated to Inventions II and IV. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects because Inventions I and II are drawn to a method of producing protein in a cell and Inventions II and IV are drawn to methods of preventing/treating disease. The methods have different function and effect.
- 3. Inventions I-IV are unrelated to Invention V. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects as Inventions I-IV are drawn to methods of inducing expression of protein in cells and methods of preventing/treating disease while Invention V is drawn to a method of identifying a therapeutic compounds. These inventions have different functions and effects therefore they are unrelated.
- 4. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.
- 5. Because these inventions are distinct for the reasons given above and the search required for each Group is different, restriction for examination purposes as indicated is proper.

Application/Control Number: 09/834,760

Art Unit: 1635

, J.

6. A telephone call was made to Eugenia Garrett-Wackowski on January 8, 2002 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to J. Eric Angell whose telephone number is (703) 605-1165. The examiner can normally be reached on M-F (8:00-4:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John L. LeGuyader can be reached on (703) 308-0447. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

J. Eric Angell January 15, 2002 JEFFREY FREDMAN DRIMARY EXAMINER